×
About 33,735 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,593 results

Clinical analysis of patients with primary and secondary extranodal natural killer/T-ce...
https://doi.org/10.1002/hon.2894
Hematological Oncology; Li X, Yu H et. al.

Jun 1st, 2021 - Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is n...

A Review and Update with Perspective of Evidence that the Herbicide Glyphosate (Roundup...
https://doi.org/10.1016/j.clml.2021.04.009
Clinical Lymphoma, Myeloma & Leukemia; Weisenburger DD

May 30th, 2021 - Glyphosate-based formulations (GBFs), such as Roundup, are the most heavily used herbicides in the world. In 2015, the International Agency for Research on Cancer (IARC) concluded that glyphosate and GBFs are probably carcinogenic to humans (group...

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and ...
https://doi.org/10.1016/j.leukres.2021.106615
Leukemia Research; Sharda E, Patel RS et. al.

May 30th, 2021 - Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage o...

Immunodeficiency-associated Hodgkin lymphoma.
https://doi.org/10.1080/17474086.2021.1935851
Expert Review of Hematology; Carbone A, Gloghini A et. al.

May 28th, 2021 - Hodgkin lymphoma (HL) can occur in different host conditions, i.e. in the general population and immunocompromised individuals, either during HIV infection or solid organ/hematopoietic transplantation and immunosuppressive drug treatment. Areas co...

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  105 results see all →

Clinicaltrials.gov  16,825 results

Clinical analysis of patients with primary and secondary extranodal natural killer/T-ce...
https://doi.org/10.1002/hon.2894
Hematological Oncology; Li X, Yu H et. al.

Jun 1st, 2021 - Extranodal natural killer (NK)/T-cell lymphoma (NKTL) is a rare non-Hodgkin lymphoma that rarely arise exclusively in or metastasizes to the central nervous system (CNS). Globally, CNS involvement of NKTL heralds a serious prognosis and there is n...

A Review and Update with Perspective of Evidence that the Herbicide Glyphosate (Roundup...
https://doi.org/10.1016/j.clml.2021.04.009
Clinical Lymphoma, Myeloma & Leukemia; Weisenburger DD

May 30th, 2021 - Glyphosate-based formulations (GBFs), such as Roundup, are the most heavily used herbicides in the world. In 2015, the International Agency for Research on Cancer (IARC) concluded that glyphosate and GBFs are probably carcinogenic to humans (group...

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and ...
https://doi.org/10.1016/j.leukres.2021.106615
Leukemia Research; Sharda E, Patel RS et. al.

May 30th, 2021 - Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage o...

Immunodeficiency-associated Hodgkin lymphoma.
https://doi.org/10.1080/17474086.2021.1935851
Expert Review of Hematology; Carbone A, Gloghini A et. al.

May 28th, 2021 - Hodgkin lymphoma (HL) can occur in different host conditions, i.e. in the general population and immunocompromised individuals, either during HIV infection or solid organ/hematopoietic transplantation and immunosuppressive drug treatment. Areas co...

see more →

News  1,097 results

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 25th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

Combo Provides 'Broad Benefit' Across NHL Subtypes
https://www.medscape.com/viewarticle/949208

Apr 12th, 2021 - The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial...

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing. A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

see more →

Patient Education  4 results see all →